Key benchmarks hit fresh intraday low in morning trade amid profit booking triggered by weak Asian stocks. The Nifty corrected below 12,300 mark. At 10:24 IST, the S&P BSE Sensex, dropped 208.27 points or 0.5% and traded at 41,744.36. The Nifty 50 index was down 64.55 points or 0.52% at 12,297.75.
In the broader market, the S&P BSE Mid-Cap index was up 0.22% while the S&P BSE Small-Cap index rose 0.35%. Both these indices outperformed the main stock indices.
The market breadth, indicating the overall health of the market, was negative. On the BSE, 906 shares rose and 947 shares fell. A total of 99 shares were unchanged. In Nifty 50 index, 14 stocks advanced while 36 stocks declined.
Q3 Earnings:
Den Networks (up 3.2%), Larsen & Toubro Infotech (up 2.81%), Sterlite Technologies (up 1.5%), Tinplate Company (down 1.16%) and Reliance Industrial Infrastructure (down 0.73%) will announce Q3 earnings today.
Mindtree jumped 3.73%. On consolidated basis, the IT firm reported 45.93% rise in net profit to Rs 197 crore on 3.42% increase in revenue to Rs 2,000.10 crore in Q3 December 2019 over Q2 September 2019. Digital business grew by 13.5% y-o-y.
Wipro fell 3.5%. On consolidated basis, the IT major reported 3.79% decline in net profit to Rs 2,455.90 crore on 2.28% increase in revenue to Rs 15,470.50 crore in Q3 December 2019 over Q2 September 2019. IT services segment revenue rose 3.03% to Rs 15,100.60 crore crore in Q3 December 2019 over Q2 September 2019. In dollar terms, IT services segment revenue was at $2,094.8 million, a sequential growth of 2.2%.
The company expects revenue from IT services business to be in the range of $2,095 million to $2,137 million. This translates to a dull sequential growth of 0.0% to 2.0%.
Stocks in Spotlight:
Shares of Lemon Tree Hotel were trading 0.45% higher at Rs 56.2. The company announced opening a hotel in Rishikesh, Uttarakhand, under the brand 'Lemon Tree Premier'. The hotel is located on the bank of Ganga and features 65 well-appointed rooms and suites.
Sun Pharmaceutical Industries was up 0.3%. The drug major and Rockwell Medical entered into a licensing agreement for commercializing Triferic in India. In an exchange filing made before market hours today, Sun Pharma announced that one of its wholly-owned subsidiaries has entered into exclusive licensing and supply agreements with Rockwell Medical Inc. (Rockwell), to commercialize Rockwell's Triferic, a proprietary iron replacement and haemoglobin maintenance drug, for treating anaemia in hemodialysis patients in India. Triferic is approved in USA.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
